atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase...

Reunion Neuroscience Inc. Provides 2023 Corporate Update

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for...

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in...

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”,...

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke...

PT380 – Microdosing, Talking to Physicians About Psychedelics, and Nurses as...

Psychedelics Weekly – Psilocybin and Stress Response, the Minnesota Medical Association...

Load more